Senseonics (NYSE:SENS) announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) ...

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of ...

Senseonics (SENS) announced it has filed for CE Mark registration for the Eversense 365 CGM system.Maximize Your Portfolio with Data Driven ...

The Eversense 365 long-term implantable CGM. [Image courtesy of Senseonics/Ascensia] Senseonics (NYSE:SENS) announced preliminary financial results for 2024 as it considers a reverse stock split.

On December 9, the company revealed the new CGM's early launch indicators. Senseonics noted that "since launch, Eversense 365 has already shown a 42% increase in the number of providers ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...

“2024 was a tremendous year for Senseonics, achieving our long-term ... our position in the marketplace through the newly created CGM division of our commercial partner, Ascensia, and our ...

GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...